Related Experiment Video

Updated: Apr 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer

Rosa Greasley1, Mohammad Khabazhaitajer1, Derek J Rosario2

  • 1The Department of Oncology, The University of Sheffield, Sheffield, UK.

Cancer Management and Research
|June 26, 2015
PubMed

Insights

Enzalutamide, a new anti-androgen therapy, targets multiple steps in prostate cancer progression. Clinical trials are evaluating its efficacy for advanced, castration-resistant prostate cancer, offering potential new hope.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is a leading cause of cancer death in men.
  • Castration-resistant prostate cancer (CRPC) presents a significant therapeutic challenge.
  • Understanding CRPC development mechanisms is crucial for new treatment strategies.

Purpose of the Study:

  • To review the mechanisms of CRPC development.
  • To evaluate enzalutamide as a novel androgen-receptor signaling inhibitor.
  • To discuss the potential of enzalutamide in treating advanced prostate cancer.

Main Methods:

  • Review of current scientific literature on CRPC.
  • Analysis of data from human clinical trials of enzalutamide.
  • Exploration of androgen receptor signaling pathways.

Main Results:

  • Enzalutamide targets multiple steps in androgenic stimulation.
  • Clinical trials are investigating enzalutamide's efficacy in advanced prostate cancer.
  • Potential therapeutic benefits and challenges like resistance are being studied.

Conclusions:

  • Enzalutamide represents a promising second-generation anti-androgen therapy.
  • Further research and clinical trials are essential to establish its role in CRPC treatment.
  • Addressing therapy resistance and cross-resistance is critical for optimal patient outcomes.
Keywords:
MDV3100androgen receptoranti-androgenenzalutamidemetastatic castrate resistant prostate cancer

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K